Regeneron Pharmaceuticals, Inc. received approval from the U.S. FDA for the PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination with platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations. Patients must either have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation.    The approval is based on data from the global Phase 3 trial, EMPOWER-Lung ...